【レポートの概要（一部）】
1. Report Overview
1.1 Global Asthma and COPD Therapies Market Overview
1.2 Global Asthma and COPD Therapies Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Introduction to Asthma and COPD Therapies
2.1 The Pharmaceutical Industry: A Very Brief Overview
2.2 Overview of Respiratory Diseases
2.2.1 Classifying Respiratory Diseases: Obstructive and Restrictive
2.3 What Is Asthma?
2.3.1 Trends in Asthma Prevalence
2.3.2 Pathophysiology of Asthma
2.3.3 Symptoms of Asthma
2.3.4 Causes and Triggers for Asthma
2.3.5 Treatment of Asthma
2.3.6 Guidelines for Asthma Treatment
2.3.7 Drug Treatments for Asthma
2.3.8 Drug Delivery Methods in Asthma
2.4 What Is Chronic Obstructive Pulmonary Disease (COPD)?
2.4.1 Trends in COPD Prevalence
2.4.2 Pathophysiology of COPD
2.4.3 Signs and Symptoms of COPD
2.4.4 Treatment of COPD
2.4.5 Drug Treatments for COPD
2.4.6 Guidelines for COPD Treatment
2.5 Major Drug Classes in the Treatment of Asthma and COPD
2.5.1 Bronchodilators
2.5.1.1 Beta2-Agonists
2.5.1.2 Anticholinergics
2.5.2 Anti-Inflammatory Drugs
2.5.2.1 Corticosteroids
2.5.2.2 Leukotriene Receptor Antagonists
2.5.2.3 Monoclonal Antibodies in the Treatment of Respiratory Disease
2.5.3 Combination Drugs
2.6 Phases of Clinical Trials
2.7 Scope of this Report
2.8 Currency Exchange Rates in This Report
3. Asthma and COPD Therapies: World Market 2015-2025
3.1 The World Respiratory Drugs Market by Therapeutic Area
3.2 The World Asthma and COPD Therapies Market in 2014
3.2.1 Leading Asthma and COPD Therapies
3.2.2 Leading Companies in the Asthma and COPD Therapies Market
3.3 World Asthma and COPD Therapies Market: Sales Forecast by Therapeutic Area, 2015-2025
3.3.1 World Asthma Therapies Market: Sales Forecast 2015-2025
3.3.2 World COPD Therapies Market: Sales Forecast 2015-2025
3.4 World Asthma and COPD Therapies Market: Sales Forecast by Drug Class 2015-2025
3.5 Combination Drugs Lead the Asthma and COPD Therapies Market
3.6 How Will Segmental Market Shares Change to 2025?
3.6.1 World Asthma and COPD Therapies Market: Drivers and Restraints 2015-2025
3.7 Asthma and COPD Therapies: Trends and Developments
3.7.1 FDA Requires Replacement of CFC Inhalers with HFA Inhalers
3.7.2 The WISDOM Trial: Will Steroids Lose Their Role in COPD?
4. Leading National Markets 2015-2025
4.1 Regional Breakdown of the World Asthma and COPD Therapies Market
4.2 World Asthma and COPD Therapies Market: Regional Forecast 2015-2025
4.2.1 How Will Regional Market Shares Change to 2025?
4.3 National Breakdown of the World Asthma and COPD Therapies Market
4.4 World Asthma and COPD Therapies Market: National Markets Forecast 2015-2025
4.4.1 How Will National Market Shares Change to 2025?
4.5 The US Asthma and COPD Therapies Market 2015-2025
4.5.1 US Asthma and COPD Therapies Market Forecast 2015-2025
4.5.2 US Asthma and COPD Therapies Market: Trends and Developments
4.5.2.1 Increasing COPD Prevalence in the US
4.5.2.2 FDA Issues Draft Guidance on Generic Inhaler Bioequivalence
4.5.2.3 Pharmacy Benefit Managers Alter Formulary Status of Advair
4.6 Japanese Asthma and COPD Therapies Market 2015-2025
4.6.1 Japanese Asthma and COPD Therapies Market Forecast 2015-2025
4.6.2 Japanese Asthma and COPD Therapies Market: Trends and Developments
4.6.2.1 Generic Penetration to Reach 60% by 2018?
4.6.2.2 Japanese Pharmaceutical Industry Regulatory Reform
4.7 EU5 Asthma and COPD Therapies Market 2015-2025
4.7.1 German Asthma and COPD Therapies Market Forecast 2015-2025
4.7.2 French Asthma and COPD Therapies Market Forecast 2015-2025
4.7.3 UK Asthma and COPD Therapies Market Forecast 2015-2025
4.7.4 Italian Asthma and COPD Therapies Market Forecast 2015-2025
4.7.5 Spanish Asthma and COPD Therapies Market Forecast 2015-2025
4.7.6 EU5 Asthma and COPD Therapies Market: Trends and Developments
4.7.6.1 Germany: Reform of AMNOG Pharmaceutical Rebate Law
4.7.6.2 France: Social Security Finance Bill 2015
4.7.6.3 UK: Improving Asthma and COPD Patient Outcomes
4.7.6.4 Italy: Austerity Measures Limiting Growth
4.7.6.5 Spain: The Start of Recovery in the Spanish Economy
4.8 BRIC Asthma and COPD Therapies Market 2015-2025
4.8.1 Chinese Asthma and COPD Therapies Market Forecast 2015-2025
4.8.2 Chinese Asthma and COPD Therapies Market: Trends and Developments
4.8.2.1 China’s Industrial Future and Asthma/COPD
4.8.2.2 Expansion of Healthcare Coverage and Reimbursement
4.8.2.3 Price Controls and the Anhui Model
4.8.3 Brazilian Asthma and COPD Therapies Market Forecast 2015-2025
4.8.4 Brazilian Asthma and COPD Therapies Market: Trends and Developments
4.8.4.1 Increasing Access to Medicines
4.8.5 Indian Asthma and COPD Therapies Market Forecast 2015-2025
4.8.6 Indian Asthma and COPD Therapies Market: Trends and Developments
4.8.6.1 Drug Prices Control Order 2014
4.8.6.2 Expansion of Healthcare Provision
4.8.7 Russian Asthma and COPD Therapies Market Forecast 2015-2025
4.8.8 Russian Asthma and COPD Therapies Market: Trends and Developments
4.8.8.1 No Embargo on Foreign Drug Imports
4.8.8.2 Pharma2020 and the Russian Pharmaceutical Industry
4.9 Mexican Asthma and COPD Therapies Market 2015-2025
4.9.1 Mexican Asthma and COPD Therapies Market Forecast 2015-2025
4.9.2 Mexican Asthma and COPD Therapies Market: Trends and Developments
4.9.2.1 Seguro Popular: Mexican Healthcare Reform
4.9.2.2 COFEPRIS: Regulatory Changes and Improvements
4.9.2.3 Mexico’s Agreement for Innovation
5. Bronchodilator Monotherapy Market 2015-2025
5.1 Introduction to Bronchodilator Monotherapy
5.2 The Bronchodilator Monotherapy Market in 2014
5.2.1 Leading Bronchodilators in 2014
5.3 Bronchodilator Monotherapy: Market Forecast 2015-2025
5.4 How Will Market Shares by Drug Class Change to 2025?
5.5 The Short-Acting Beta2-Agonist (SABA) Market 2015-2025
5.5.1 Leading SABAs in 2014
5.5.2 SABAs: Market Forecast 2015-2025
5.5.3 Market Share of Leading SABAs to 2025
5.5.4 Ventolin (salbutamol, GSK)
5.5.4.1 Ventolin: Sales Forecast 2015-2025
5.5.5 ProAir (salbutamol, Teva)
5.5.5.1 ProAir: Sales Forecast 2015-2025
5.5.6 Proventil (salbutamol, Merck)
5.5.6.1 Proventil: Sales Forecast 2015-2025
5.5.7 Xopenex (levosalbutamol, Dainippon Sumitomo)
5.5.7.1 Xopenex: Sales Forecast 2015-2025
5.6 The Long-Acting Beta2-Agonist (LABA) Market 2015-2025
5.6.1 Leading LABAs in 2014
5.6.2 LABAs: Market Forecast 2015-2025
5.6.3 Market Share of Leading LABAs to 2025
5.6.4 Foradil (formoterol, Merck/Novartis)
5.6.4.1 Foradil: Sales Forecast 2015-2025
5.6.5 Brovana (salmeterol, GSK)
5.6.5.1 Brovana: Sales Forecast 2015-2025
5.6.6 Arcapta/Onbrez (indacaterol, Novartis)
5.6.6.1 Arcapta/Onbrez: Sales Forecast 2015-2025
5.6.7 Serevent (arfomoterol, Dainippon Sumitomo)
5.6.7.1 Serevent: Sales Forecast 2015-2025
5.7 The Anticholinergics Market 2015-2025
5.7.1 Leading Anticholinergics in 2014
5.7.2 Anticholinergics: Market Forecast 2015-2025
5.7.3 Market Share of Leading Anticholinergics to 2025
5.7.4 Spiriva (tiotropium, Boehringer Ingelheim)
5.7.4.1 Spiriva: Sales Forecast 2015-2025
5.7.5 Spiriva: Recent Developments
5.7.5.1 Safety Concerns and the UPLIFT Trial
5.7.5.2 Results of the POET Study
5.7.5.3 Competition from Combination Products
5.7.6 Atrovent (ipratropium, Boehringer Ingelheim)
5.7.6.1 Atrovent: Sales Forecast 2015-2025
5.7.7 Eklira/Tudorza/Bretaris (aclidinium, AstraZeneca/Menarini)
5.7.7.1 Eklira/Tudorza/Bretaris: Sales Forecast 2015-2025
6. Anti-Inflammatory Drugs Market 2015-2025
6.1 Introduction to Anti-Inflammatory Drugs
6.2 The Anti-Inflammatory Drugs Market in 2014
6.2.1 Leading Anti-Inflammatory Drugs in 2014
6.3 Anti-Inflammatory Drugs: Market Forecast 2015-2025
6.4 How Will Market Shares by Drug Class Change to 2025?
6.5 The Corticosteroids Market 2015-2025
6.5.1 Leading Corticosteroids in 2014
6.5.2 Corticosteroids: Market Forecast 2015-2025
6.5.3 Market Share of Leading Corticosteroids to 2025
6.5.4 Flixotide/Flovent (fluticasone propionate, GSK)
6.5.4.1 Flixotide/Flovent: Sales Forecast 2015-2025
6.5.5 Pulmicort (budesonide, AstraZeneca)
6.5.5.1 Pulmicort: Sales Forecast 2015-2025
6.5.6 QVAR (beclometasone, Teva)
6.5.6.1 QVAR: Sales Forecast 2015-2025
6.5.7 Asmanex (mometasone, Merck)
6.5.7.1 Asmanex: Sales Forecast 2015-2025
6.6 The Anti-Leukotrienes Market 2015-2025
6.6.1 Leading Anti-Leukotrienes in 2014
6.6.2 Anti-Leukotrienes: Market Forecast 2015-2025
6.6.2.1 Market Share of Leading Anti-Leukotrienes to 2025
6.6.3 Singulair (montelukast, Merck)
6.6.3.1 Singulair: Sales Forecast 2015-2025
6.7 The Monoclonal Antibodies Market 2015-2025
6.7.1 Monoclonal Antibodies: Market Forecast 2015-2025
6.7.1.1 Market Share of Leading Monoclonal Antibodies to 2025
6.7.2 Xolair (omalizumab, Novartis/Roche)
6.7.2.1 Xolair: Sales Forecast 2015-2025
6.7.3 Cinquil (reslizumab, Teva)
6.7.3.1 Cinquil: Sales Forecast 2015-2025
6.7.4 Mepolizumab (Bosatria, GSK)
6.7.4.1 Mepolizumab: Sales Forecast 2015-2025
6.7.5 Benralizumab (MEDI-563, AstraZeneca/Kyowa Hakko Kirin)
6.7.5.1 Benralizumab: Sales Forecast 2015-2025
6.7.6 Lebrikizumab (RG3637, Roche)
6.7.6.1 Lebrikizumab: Sales Forecast 2015-2025
6.7.7 Dupilumab (REGN668, Regeneron/Sanofi)
6.7.7.1 Dupilumab: Sales Forecast 2015-2025
7. Combination Drugs Market 2015-2025
7.1 Introduction to Combination Drugs
7.1.1 Leading Combination Drugs in 2014
7.2 Combination Drugs: Market Forecast 2015-2025
7.3 How Will Market Shares by Drug Change to 2025?
7.3.1 Advair/Seretide (fluticasone/salmeterol, GSK)
7.3.1.1 Advair/Seretide: Sales Forecast 2015-2025
7.3.2 Symbicort (budesonide/formoterol fumarate, AstraZeneca)
7.3.2.1 Symbicort: Sales Forecast 2015-2025
7.3.2.2 Symbicort: The SMART Concept
7.3.3 Combivent (ipratropium/salbutamol, Boehringer Ingelheim)
7.3.3.1 Combivent: Sales Forecast 2015-2025
7.3.4 Dulera (formoterol/mometasone, Merck)
7.3.4.1 Dulera: Sales Forecast 2015-2025
7.3.5 Breo/Relvar Ellipta (vilanterol/fluticasone furoate, GSK)
7.3.5.1 Breo/Relvar: Sales Forecast 2015-2025
7.4 Recently Launched Combination Drugs
8. Leading Companies in the Asthma and COPD Therapies Market
8.1 Asthma and COPD Therapies: Increasing Competition
8.1.1 Leading Companies in Asthma and COPD in 2015
8.1.2 Leading Companies: Market Forecast 2015-2025
8.1.3 How Will Leading Companies’ Market Shares Change to 2025?
8.2 GSK
8.2.1 GSK: Asthma and COPD Therapies
8.2.2 GSK: Sales Forecast 2015-2025
8.2.3 GSK: Products in Development
8.2.4 GSK: Recent Developments
8.2.4.1 Recently Launched Combination Drugs
8.2.4.2 GSK Divests OTC Products
8.2.4.3 GSK Asset Swap with Novartis to Restructure Consumer Health
8.2.4.4 GSK Presents Data on Eosinophil Levels and COPD
8.3 Boehringer Ingelheim
8.3.1 Boehringer Ingelheim: Asthma and COPD Therapies
8.3.2 Boehringer Ingelheim: Sales Forecast 2015-2025
8.3.3 Boehringer Ingelheim: Asthma and COPD Product Development Ceased
8.3.4 Boehringer Ingelheim: Recent Developments
8.3.4.1 Expansion of Respimat Manufacturing Capacity
8.3.4.2 Respimat Safety Concerns and the TIOSPIR Study
8.3.4.3 Ben Venue Laboratories Shut Down
8.3.4.4 Sale of Roxane Laboratories
8.4 AstraZeneca
8.4.1 AstraZeneca: Asthma and COPD Therapies
8.4.2 AstraZeneca: Sales Forecast 2015-2025
8.4.3 AstraZeneca: Products in Development
8.4.4 AstraZeneca: Recent Developments
8.4.4.1 AstraZeneca Acquires Almirall’s Respiratory Portfolio
8.4.4.2 Acquisition of Pearl Therapeutics Expanded AstraZeneca’s Combination Drug Pipeline
8.4.4.3 AstraZeneca Rejects Pfizer Takeover Bid
8.4.4.4 AstraZeneca Acquires Right to Actavis’ Branded Respiratory Portfolio in US and Canada
8.5 Merck & Co. (Merck)
8.5.1 Merck: Asthma and COPD Therapies
8.5.2 Merck: Sales Forecast 2015-2025
8.5.3 Merck: Products in Development
8.5.4 Merck: Recent Developments
8.5.4.1 Bayer Acquires Merck’s Consumer Health Business
8.5.4.2 FDA Rejects Singulair OTC Switch
8.5.4.3 Takeda Ended Co-Promotion of Daxas with Merck
8.6 Novartis
8.6.1 Novartis: Asthma and COPD Therapies
8.6.2 Novartis: Sales Forecast 2015-2025
8.6.3 Novartis: Products in Development
8.6.4 Novartis: Recent Developments
8.6.4.1 Novartis Restructures Following Strategic Review
8.6.4.2 Novartis Presents Data on Ultibro and Seebri
8.6.4.3 Pfizer Promotes Two Novartis COPD drugs in the UK
8.7 Roche
8.7.1 Roche: Asthma and COPD Therapies
8.7.2 Roche: Sales Forecast 2015-2025
8.7.3 Roche: Products in Development
8.8 Teva
8.8.1 Teva: Asthma and COPD Therapies
8.8.2 Teva: Sales Forecast 2015-2025
8.8.3 Teva: Products in Development
8.8.4 Teva: Recent Developments
8.8.4.1 Launch of DuoResp Spiromax
9. Asthma and COPD Therapies Pipeline Analysis 2015-2025
9.1 A Strong Asthma and COPD Pipeline
9.2 The Bronchodilators Pipeline
9.2.1 Bronchodilators: Phase 3 Pipeline
9.2.1.1 PX1439 and PX1442 (Prosonix)
9.2.1.2 PT001 (glycopyrronium, AstraZeneca)
9.2.1.3 Spiriva Respimat (tiotropium, Boehringer Ingelheim)
9.2.1.4 GW642444 (vilanterol, GSK)
9.2.1.5 KRP-AB1102 (aclidinium, Kyorin Pharmaceutical)
9.2.1.6 Seebri Breezhaler (glycopyrronium, Novartis/Vectura)
9.2.1.7 QVAR BAI (beclometasone, Teva)
9.2.1.8 Albuterol MDPI/Albuterol Spiromax (salbutamol, Teva)
9.3 The Anti-Inflammatory Drugs Pipeline
9.3.1 Anti-Inflammatory Drugs: Phase 3 Pipeline
9.3.1.1 PSX1001 and PSX1050 (fluticasone propionate pMDI, Prosonix)
9.3.1.2 Masitinib (tyrosine kinase inhibitor, AB Science)
9.3.1.3 Inhaled Alpha-1 Antitrypsin (Kamada/Chiesi Farmaceutici)
9.3.1.4 VR506 (fluticasone propionate DPI, Vectura)
9.3.1.5 Favolir (budesonide, Vectura)
9.4 The Combination Drugs Pipeline
9.4.1 Combination Drugs: Phase 3 Pipeline
9.4.1.1 PSX2005 (fluticasone/salmeterol, Prosonix)
9.4.1.2 LAS40464 (aclidinium/formoterol, AstraZeneca)
9.4.1.3 PT003 (glycopyrronium/formoterol, AstraZeneca)
9.4.1.4 Tiotropium/Olodaterol Fixed-Dose Combination (LAMA/LABA, Boehringer Ingelheim)
9.4.1.5 Easyhaler Combination Drugs (Orion)
9.4.1.6 VR632 (ICS/LABA, Vectura/Sandoz)
9.5 Other Asthma and COPD Drugs Pipeline
10. Qualitative Analysis of the Asthma and COPD Therapies Market 2015-2025
10.1 SWOT Analysis of the Asthma and COPD Therapies Market
10.2 Strengths
10.2.1 Increasing Prevalence and Disease Burden
10.2.2 High Costs of Treatment
10.2.3 The Changing Perception of COPD
10.2.4 Patient Education: Understanding the Severity of Respiratory Disease
10.2.5 Lifecycle Management Strategies to Counter Patent Expiry
10.2.6 Advanced Inhaler Technologies to Counter Generic Erosion
10.2.7 Developments in Diagnostics
10.2.7.1 Diagnostic Imaging: Parametric Response Mapping for COPD
10.2.7.2 Biological Markers in COPD
10.3 Weaknesses
10.3.1 Under-Diagnosis: the ‘Ghost Population’
10.3.2 Side-Effects of Drug Classes
10.3.3 Patent Cliff for Devices
10.3.4 Low Patient Adherence
10.3.5 Costing Pressures in both Developed and Emerging Markets
10.4 Opportunities
10.4.1 Patient Phenotyping and Personalised Medicine
10.4.2 A Strong R&D Pipeline
10.4.2.1 Ultra-Long-Acting Beta2-Agonists
10.4.2.2 Muscarinic Antagonists and Beta2-Agonists (MABAs)
10.4.2.3 Monoclonal Antibodies
10.4.2.4 LAMA/LABA Combinations
10.4.3 Opportunities in Telehealth
10.5 Threats
10.5.1 Patent Expiry and Generic Competition
10.5.2 Pharmacy Benefit Managers and Cost Control
10.5.3 The WISDOM Trial Could Reduce Steroid Use in COPD
10.6 Porter’s Five Forces Analysis of the Asthma and COPD Therapies Market
10.6.1 Rivalry Among Competitors [Medium]
10.6.2 Threat of New Entrants [Medium]
10.6.3 Power of Suppliers [Medium]
10.6.4 Power of Buyers [High]
10.6.5 Threat of Substitutes [Low]
11. Research Interviews
11.1 Interview with Professor Clive Page, Professor of Pharmacology and Director of the Sackler Institute of Pulmonary Pharmacology, King’s College London
11.1.1 Treating Different Phenotypes of Asthma and COPD
11.1.2 Personalised Medicine and Improved Existing Drug Classes
11.1.3 Phenotyping of Asthma/COPD, Diagnosis and Treatment
11.1.4 WISDOM Trial: Questioning the Role of Steroids in COPD
11.1.5 Monoclonal Antibodies in Severe Asthma
11.1.6 Healthcare Costs and the Importance of Prevention
11.1.7 Areas to Improve Diagnosis and Treatment of Asthma
11.1.8 The Importance of Adherence and Early Diagnosis
11.1.9 Developments in Alpha-1 Antitrypsin Deficiency
11.1.10 Other Trends and Developments in Asthma and COPD
11.2 Interview with a Company Developing Pipeline Drugs for Asthma and COPD
11.2.1 Asthma and COPD Treatments in 2014-2024
11.2.2 Personalised Therapies for Asthma and COPD
11.2.3 Drivers and Restraints in the Market
11.2.4 The Outlook for the Asthma and COPD Market
12. Conclusions
12.1 Asthma and COPD Therapies: A Maturing Market
12.2 The World Asthma and COPD Therapies Market in 2014
12.2.1 Current Leading Asthma and COPD Therapies Segments
12.2.2 Leading Asthma and COPD Therapies
12.2.3 Leading Asthma and COPD Therapies Companies
12.2.4 Leading Regional and National Markets
12.3 World Asthma and COPD Therapies Market Forecast 2015-2025
12.4 The Future of the Asthma and COPD Therapies Market?
12.4.1 Growth in Anti-Inflammatory and Combination Drugs
12.4.2 Towards Personalised Medicine
12.4.3 Unmet Needs in Asthma and COPD
12.4.4 Strategies for Growth in 2015-2025
13. Glossary
Appendix A
Appendix B
【レポート販売概要】
■ タイトル：喘息及びCOPD（慢性閉塞性肺疾患）治療の世界市場予測：気管支拡張薬、抗炎症薬■ 英文：Asthma and COPD Therapies Market Forecast 2015-2025: Opportunities for Leading Companies
■ 発行日：2015年10月
■ 調査会社：visiongain
■ 商品コード：VGAIN5102610
■ 調査対象地域：グローバル
- 閉経後膣萎縮（PVA）：世界市場（医薬品市場予測及び分析～2022）PharmaPoint: Postmenopausal Vaginal Atrophy - Global Drug Forecast and Market Analysis to 2022 Summary Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over the past decade, it is expected to undergo a considerable change between 2012 and 2022. This market has historically had a large untreated population due to: low diagnosis rates, safety issues with the exi …
- 全地形対応車(ATV)用変速機システムの世界市場2019-2023About this market The growing demand for ATVs in APAC will trigger the market’s growth in the forthcoming years. Emerging economies including India and China are witnessing an increase in the demand for ATVs in recent years mainly due to the growing awareness of applications of ATVs among the consumers. In addition, off-road enthusiasts are also increasingly looking for ATVs for engaging in off-ro …
- 界面活性剤の世界市場：インサイト、市場機会、市場シェア、市場予測The global surfactants market is expected to grow around $46,840 million by 2022 at a CAGR of 5.45% during 2016-2022. Surfactants are organic chemicals that consist of hydrophilic and hydrophobic parts in a molecule. These molecules tend to reduce the surface tension of the liquid (solvent) in which it is dissolved. Wide range of applications such as personal care, cosmetic etc. helps in boosting …
- 貨物輸送の世界市場：液体貨物、バラ積み乾貨物、一般貨物、コンテナー貨物In the past decade it has been seen that world economic activity, trade liberalization and current growth in Asian economies is the main driving cause in global marine industry. In the upcoming years, the industry is projected to get benefit from improving trade levels with greater demand from the logistics and shipping sectors. Trade between Asian countries and the rest of the world is expected t …
- 関節リウマチ（Rheumatoid Arthritis）治療薬の世界市場予測および分析PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2023 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow t …
- 再生可能エネルギー政策分析：May 2013Renewable Policy Analysis - May 2013 Summary The “Renewable Policy Analysis” provides in depth study of the major renewable policy developments across the globe. It gives regulatory and other associated updates for the global renewable energy market which can help the individual/company to frame their business strategies while minimizing regulatory risks. For the May 2013 issue, it covers two feat …
- プロダクションプリンターの世界市場2016-2020About Production Printers Production printers are used for volume printing with a print speed of more than 60 ppm. These prints are used for commercial purposes such as printing books, manuals, marketing collaterals, packaging, and transactional documents. Production printers commonly use three types of inks, which include water-based, solvent, and ultra violet (UV)-cured inks. Water based inks ac …
- 製造産業向け自動マテリアルハンドリングシステムの世界市場：無人搬送車（AGV）、自動倉庫、自動クレーン、ロボット装置The automated material handling (AMH) refers to any automation that eliminates the need for human labor in moving, packaging, and storing material at the manufacturing floor. Automated material handling provides many advantages such as improved production quality, elimination of manual labor, reduced labor and manufacturing costs, improved safety and efficiency, maximization of floor space, and in …
- South Korea Pharmaceutical Market Outlook 2013South Korea Pharmaceutical Market Outlook 2013 Summary GBI Research’s new report, “South Korea Pharmaceutical Market Outlook 2013” provides in-depth analysis of the trends, issues and challenges facing the South Korean pharmaceutical market. The report also provides competitive benchmarking for the country’s leading pharmaceutical companies and analyzes the M&A (Mergers and Acquisitions) and strat …
- モノマー市場動向：February 2013Monomer World – February 2013 Summary Global monomer prices in February 2013 stabilized after witnessing a steep rise in January due to restricted supply. Asia and Europe witnessed moderate increases in monomer prices, while North America witnessed a decline in prices in February. Scope - Analyses monthly price trends in Asia, Europe and North America region - Details significant developments in t …
- MRIシステム（核磁気共鳴画像診断装置）の世界市場Developing Asian countries such as China and India are lucrative markets for MRI systems owing to the growing aging population and rising awareness about early diagnosis in these countries. The report segments the global MRI systems market by architecture, field strength, application, and region. High-field MRI (1.5T) accounted for the largest share of the global MRI systems market. However, the v …
- 食物繊維の世界市場：不溶性食物繊維（セルロース、キトサン、キチン質、リグニン、難消化性デンプン）、可溶性食物繊維（イヌリン、ポリデキストロース、ペクチン、ベータグルカン）The dietary fibers market has grown exponentially in the last few years and this trend is projected to continue. The market was valued at USD 2.32 billion in 2015 and is projected to grow at a CAGR of 13.2% from 2015 to 2020. The market is primarily driven by factors such as rising incidence of obesity, diabetes, other diagnosed food intolerances, and growing consumer awareness to address these co …
- 二輪車用電気式燃料噴射システムの世界市場2016-2020About Fuel Management System The fuel management system of vehicles is responsible for supplying the fuel to the combustion chamber, while maintaining the fuel-air ratio. The ratio is measured and maintained with the help of a stoichiometric method and an automatic fixture removal (AFR) process, which generate a balanced fuel-to-air ratio for combustion. The typical fuel-air ratio for gasoline and …
- グローバルWCMS（Webコンテンツ管理システム）市場（2014-2018）About WCMS WCMS is a software tool used to create, manage, store, and deploy content such as text, audio, graphics, videos, and photos, on web pages. This system is used by both technical and non-technical staff to manage the creation of structured web pages. It enhances hosting speed and security, and helps in developing content-rich and error-free websites, establishing a robust multi-channel ma …
- 血管内超音波検査(IVUS)装置（医療機器）のグローバル市場（2012-2018）Global Intravascular Ultrasound (IVUS) sector is projected to reach US$618 million by 2016. The North America accounts for nearly 33% (2015) of the global share while Europe claims approximately 17% (2018). Asia-Pacific is the fastest growing region with a CAGR of 10.3% driving a market value of US$252 million by 2015. Among the product types, IVUS Catheters accounts nearly half of the market valu …
